Bulletin
Investor Alert

New York Markets Open in:

Cerecor Inc.

NAS: CERC

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 25, 2020, 6:46 p.m.

/zigman2/quotes/201368871/composite

$

2.45

Change

+0.02 +0.82%

Volume

Volume 2,372

Quotes are delayed by 20 min

/zigman2/quotes/201368871/composite

Previous close

$ 2.25

$ 2.43

Change

+0.18 +8.00%

Day low

Day high

$2.26

$2.44

Open

52 week low

52 week high

$1.52

$6.19

Open

Company Description

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company...

Cerecor, Inc. engages in the development and commercialization of treatments for rare pediatric and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Valuation

Price to Sales Ratio

34.24

Price to Book Ratio

11.40

Enterprise Value to Sales

32.76

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

375,020.00

Income Per Employee

-903,931.00

Receivables Turnover

0.97

Total Asset Turnover

0.13

Liquidity

Current Ratio

1.46

Quick Ratio

1.46

Cash Ratio

0.93

Profitability

Gross Margin

63.08

Operating Margin

-281.37

Pretax Margin

-236.88

Net Margin

-241.04

Return on Assets

-30.57

Return on Equity

-77.66

Return on Total Capital

-64.88

Return on Invested Capital

-56.75

Capital Structure

Total Debt to Total Equity

6.04

Total Debt to Total Capital

5.69

Total Debt to Total Assets

3.51

Long-Term Debt to Equity

5.30

Long-Term Debt to Total Capital

4.99

Officers and Executives

Name Age Officer Since Title
Mr. Michael F. Cola 59 2020 Chief Executive Officer & Director
Mr. Christopher Sullivan 35 2018 Vice President-Finance
Dr. Garry Arthur Neil 65 2020 Chief Medical Officer
Dr. H. Jeffrey Wilkins 57 2020 Chief Development Officer
Dr. Bernadine Heather Fraser 50 2012 VP-Clinical Operations & Project Management

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/04/2020 Armistice Capital LLC
Director
0   Acquisition at $0 per share. 0
09/04/2020 Armistice Capital LLC
Director
100,000   Acquisition at $2.2 per share. 220,000
06/10/2020 Garry Arthur Neil
Chief Scientific Officer
1,799   Acquisition at $2.28 per share. 4,101
06/10/2020 James A. Harrell
Chief Commercial Officer
6,391   Acquisition at $2.28 per share. 14,571
06/10/2020 Christopher Sullivan
Interim CFO
2,954   Acquisition at $2.28 per share. 6,735
06/09/2020 Armistice Capital LLC
Director
267,806   Acquisition at $2.52 per share. 674,871
06/09/2020 Armistice Capital LLC
Director
0   Acquisition at $0 per share. 0
06/09/2020 Armistice Capital LLC
Director
1,753,680   Acquisition at $2.5 per share. 4,384,200
06/09/2020 Michael F. Cola
Chief Executive Officer; Director
100,000   Acquisition at $2.5 per share. 250,000
06/09/2020 Michael F. Cola
Chief Executive Officer; Director
100,000   Acquisition at $2.5 per share. 250,000
06/09/2020 James A. Harrell
Chief Commercial Officer
10,000   Acquisition at $2.5 per share. 25,000
06/08/2020 Joseph M. Miller
Director
4,472   Derivative/Non-derivative trans. at $3.22 per share. 14,399
04/09/2020 Simon C. Pedder
Executive Chairman of the Bd; Director
20,901   Derivative/Non-derivative trans. at $2.57 per share. 53,715
04/03/2020 Armistice Capital LLC
Director
4,280   Acquisition at $2.16 per share. 9,244
03/31/2020 Armistice Capital LLC
Director
26,611   Acquisition at $2.33 per share. 62,003
03/30/2020 Armistice Capital LLC
Director
49,303   Acquisition at $2.35 per share. 115,862
03/27/2020 Armistice Capital LLC
Director
36,000   Acquisition at $2.43 per share. 87,480
03/23/2020 Armistice Capital LLC
Director
1,374   Acquisition at $2.52 per share. 3,462
/news/latest/company/us/cerc

MarketWatch News on CERC

  1. Big Stock Buys at Winnebago, National CineMedia

    9:40 p.m. March 27, 2020

    - Barron's Online

  2. Cerecor started at outperform with $11 stock price target at Oppenheimer

    9:52 a.m. Jan. 10, 2020

    - Tomi Kilgore

  3. Starboard Value Urges Zayo Group to Sell Itself

    1:10 a.m. March 16, 2019

    - Barron's Online

  4. There’s Value in Damaged Papa John’s Pizza

    8:00 p.m. Oct. 5, 2018

    - Barron's Online

  5. Cerecor Inc. shares drop 37% after midstage trial failure

    9:14 a.m. Dec. 5, 2016

    - Emma Court

  6. Cerecor's stock extends slide, plunges 37% premarket after failed drug trial

    9:09 a.m. Dec. 5, 2016

    - Tomi Kilgore

  7. Cerecor says mid-stage trial of treatment for nicotine withdrawal missed its target

    9:05 a.m. Dec. 5, 2016

    - Ciara Linnane

  8. Cerecor's stock tumbles 14% premarket after drug trial fails to meet primary endpoint

    9:05 a.m. Dec. 5, 2016

    - Tomi Kilgore

  9. Cerecor's stock on track to open at all-time low

    9:06 a.m. Dec. 5, 2016

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cerc

Other News on CERC

  1. 10-Q: CERECOR INC.

    7:42 a.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  2. OPK, NBEV among premarket gainers

    8:23 a.m. July 21, 2020

    - Seeking Alpha

  3. Enrollment underway in Cerecor CERC-002 study for COVID-19 ARDS

    7:29 a.m. July 21, 2020

    - Seeking Alpha

  4. Largest Insider Trades of the Week

    9:42 a.m. June 12, 2020

    - GuruFocus.com

  5. CHK, CPE among premarket losers

    9:14 a.m. June 9, 2020

    - Seeking Alpha

  6. Cerecor (CERC) Investor Presentation - Slideshow

    6:11 p.m. June 3, 2020

    - Seeking Alpha

  7. ARNC, ALXN among premarket gainers

    9:20 a.m. May 28, 2020

    - Seeking Alpha

  8. Cerecor on go with study of CERC-002 in COVID-19 patients

    7:18 a.m. May 28, 2020

    - Seeking Alpha

  9. NVAX, LK among premarket ganers

    9:26 a.m. May 26, 2020

    - Seeking Alpha

  10. NVAX, LK among premarket gainers

    9:26 a.m. May 26, 2020

    - Seeking Alpha

  11. Aytu: A One-Trick Play

    6:24 a.m. April 1, 2020

    - Seeking Alpha

  12. Cerecor up 29% on exploratory work in COVID-19

    7:36 a.m. March 26, 2020

    - Seeking Alpha

  13. Circling Around On Cerecor

    3:25 p.m. March 23, 2020

    - Seeking Alpha

  14. Loading more headlines...

At a Glance

Cerecor, Inc.

540 Gaither Road

Suite 400

Rockville, Maryland 20850

Phone

1 4105228707

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$6.75M

Net Income

$-16.27M

Employees

18.00

/news/pressrelease/company/us/cerc

Press Releases on CERC

  1. Cerecor to Present at Upcoming Investor Conferences

    7:00 a.m. Sept. 10, 2020

    - GlobeNewswire

  2. Stocks Which Saw Increased Insider Transactions: $QRHC $CERC $APEN

    8:29 a.m. Sept. 1, 2020

    - The Market Signal

  3. Cerecor Reports Q1 2020 Results and Update

    6:30 a.m. May 7, 2020

    - GlobeNewswire

  4. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.